Updated Global Consensus Recommendations for Risk Stratification, Treatment Initiation, and Response Monitoring in Metabolic Dysfunction-Associated Steatotic Liver Disease - PubMed
3 hours ago
- #Risk Stratification
- #MASLD
- #Noninvasive Tests
- FIB-4 is endorsed as the first-line assessment for risk stratification in MASLD.
- Secondary stratification should use vibration-controlled transient elastography or Enhanced Liver Fibrosis (ELF) testing.
- Treatment with resmetirom or semaglutide is recommended for noncirrhotic MASLD with specific liver stiffness or ELF values.
- Upfront combination therapy with both drugs is not recommended.
- Pharmacologic therapy selection should involve shared decision-making, based on the patient's cardiometabolic profile.
- Treatment response at one year is defined as ≥30% reduction in liver stiffness or ≥0.5-point reduction in ELF.